CD274 and esophageal squamous cell carcinoma: The subgroup demonstrated that the combined serplulimab and chemotherapy group provided a gain of 0.18 QALYs at additional cost of $28,420.65 compared to the chemotherapy alone group for advanced ESCC patients with PD-L1 expression level of 1 ≤CPS<10.